Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.57 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.57 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.57 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.57 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.57 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.57 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.57 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CPN1 | P15169 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2836599 | 1.00 | SLC6A1 (0.57) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL856745 | 1.00 | SLC6A1 (0.57) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| Bromide SCHEMBL23881409 | 0.98 | SLC6A1 (0.55) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| Hydrochloric Acid SCHEMBL3830642 | 0.98 | SLC6A1 (0.55) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| Hydrochloric Acid SCHEMBL15662845 | 0.98 | SLC6A1 (0.55) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL2768724 | 0.89 | CYP2D6 (0.51) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL5649078 | 0.89 | CYP2D6 (0.51) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL477374 | 0.89 | CYP2D6 (0.51) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL477247 | 0.88 | ALOX15 (0.58) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| Hydrochloric Acid SCHEMBL4020092 | 0.87 | CYP2D6 (0.50) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110177786-A | Pyrazolo [1,5-A] pyridine compounds being substituted are as RET kinase inhibitor | 阿雷生物药品公司 | 2019-08-27 | — | — | CN | disclosed |
| CN-108779123-A | Fused tetracyclic compound, its composition and purposes | 泰博生物科技有限公司 | 2018-11-09 | — | — | CN | disclosed |
| CN-104379560-A | Benzamide derivative | CHUGAI PHARMACEUTICAL CO LTD | 2015-02-25 | — | — | CN | disclosed |
| EP-2166847-B1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| US-8293721-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARPE & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20100184719-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK SHARP & DOHME LLC | 2010-07-22 | — | — | US | disclosed |
| EP-2166847-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-1796466-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008156718-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
| EP-1796466-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006002047-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184719-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | CETP, APOB, MTTP | SLC6A1 3724/4885GABRA5 1738/4885GABRB2 2467/4885 |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | SLC6A1 3713/4885GABRA5 2296/4885GABRB2 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.